There has been a sharp decline in the medical technology IPO market this year -- and yet, investors seem as bullish as ever on gains in the space.
It seems to be all about the timing. Medtech executives are investing in growth, with 71% of medtech companies expanding R&D spending and 77% having bolstered headcount, according to a recent research report from Ernst & Young.
Will investors wait on markets to properly price medtech company innovation? For Mark Goldwasser of Ceros Financial, his firm’s goalpost recently shifted in terms of how much he . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
[rpt name="main"]
